Literature DB >> 32450419

HPP1 Ectodomain Shedding is Mediated by ADAM17 and is Necessary for Tumor Suppression in Colon Cancer.

Abul Elahi1, Abidemi Ajidahun1, Leah Hendrick2, Irina Getun2, Leigh Ann Humphries3, Jonathan Hernandez4, David Shibata5.   

Abstract

BACKGROUND: Hyperplastic polyposis protein 1 (HPP1) encodes a tumor-suppressive transmembrane cleavable epidermal growth factor-like ligand. It is unclear as to whether cleavage and shedding of HPP1 are essential steps in achieving its tumor suppressive properties. ADAM proteins are key players in cellular ectodomain shedding processes with ADAM17 being well characterized and representing the most likely sheddase for HPP1. In this study, we explore the mechanisms and importance of ectodomain shedding in contributing to HPP1-mediated tumor suppression.
METHODS: Baseline characterization of HPP1 ectodomain shedding and ADAM family member expression was performed in HCT116 colon cancer cells with forced overexpression of HPP1 and controls. Subsequent impact of attenuation of ADAM expression by short interfering RNA on HPP1 shedding was evaluated. Furthermore, we examined the functional impact of an uncleavable HPP1 mutant construct (HPP1-Δstalk) generated by site-directed mutagenesis. Cellular growth potential functions were analyzed by MTT and soft agar assays.
RESULTS: Select proinflammatory cytokines enhanced HPP1 ectodomain shedding, whereas short interfering RNA-mediated knockdown of ADAM17 resulted in abrogation of HPP1 ectodomain shedding. ADAM17 knockdown concomitantly resulted in increased cell proliferation and anchorage-independent growth. HPP1-Δstalk-transfected cells exhibited significantly higher proliferation and reduced STAT1 activation relative to full-length HPP1, further suggesting a critical role for ectodomain shedding in HPP1-mediated tumor suppression.
CONCLUSION: The tumor-suppressive properties of HPP1 in colorectal cancer require cleavage and shedding of its ectodomain which in turn are mediated by ADAM17. Further investigations into the regulation of HPP1 may lead to a greater understanding of epidermal growth factor-like ligand family biology and potential novel therapeutic strategies. Published by Elsevier Inc.

Entities:  

Keywords:  Colorectal cancer; EGF-like ligand; Ectodomain shedding; TMEFF2

Mesh:

Substances:

Year:  2020        PMID: 32450419      PMCID: PMC7483406          DOI: 10.1016/j.jss.2020.04.010

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  24 in total

Review 1.  ADAMs: key components in EGFR signalling and development.

Authors:  Carl P Blobel
Journal:  Nat Rev Mol Cell Biol       Date:  2005-01       Impact factor: 94.444

Review 2.  Receptor tyrosine kinases: mechanisms of activation and signaling.

Authors:  Stevan R Hubbard; W Todd Miller
Journal:  Curr Opin Cell Biol       Date:  2007-02-16       Impact factor: 8.382

3.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Authors:  Christopher P Mill; Kathleen L Gettinger; David J Riese
Journal:  Exp Cell Res       Date:  2010-11-24       Impact factor: 3.905

4.  Expression and nuclear localization of ErbB3 in prostate cancer.

Authors:  Ismaël Hervé Koumakpayi; Jean-Simon Diallo; Cécile Le Page; Laurent Lessard; Martin Gleave; Louis R Bégin; Anne-Marie Mes-Masson; Fred Saad
Journal:  Clin Cancer Res       Date:  2006-05-01       Impact factor: 12.531

5.  A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells.

Authors:  T Uchida; K Wada; T Akamatsu; M Yonezawa; H Noguchi; A Mizoguchi; M Kasuga; C Sakamoto
Journal:  Biochem Biophys Res Commun       Date:  1999-12-20       Impact factor: 3.575

6.  Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors.

Authors:  J Arribas; L Coodly; P Vollmer; T K Kishimoto; S Rose-John; J Massagué
Journal:  J Biol Chem       Date:  1996-05-10       Impact factor: 5.157

7.  Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Authors:  Daniel E H Afar; Vinay Bhaskar; Eric Ibsen; Danna Breinberg; Susan M Henshall; James G Kench; Marija Drobnjak; Rick Powers; Melanie Wong; Ferdinand Evangelista; Chris O'Hara; David Powers; Robert B DuBridge; Ingrid Caras; Ruth Winter; Terri Anderson; Nanette Solvason; Phillip D Stricker; Carlos Cordon-Cardo; Howard I Scher; John J Grygiel; Robert L Sutherland; Richard Murray; Vanitha Ramakrishnan; Debbie A Law
Journal:  Mol Cancer Ther       Date:  2004-08       Impact factor: 6.261

8.  HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers.

Authors:  J Young; K G Biden; L A Simms; P Huggard; R Karamatic; H J Eyre; G R Sutherland; N Herath; M Barker; G J Anderson; D R Fitzpatrick; G A Ramm; J R Jass; B A Leggett
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

9.  DNA methylation-associated inactivation of TGFbeta-related genes DRM/Gremlin, RUNX3, and HPP1 in human cancers.

Authors:  M Suzuki; H Shigematsu; D S Shames; N Sunaga; T Takahashi; N Shivapurkar; T Iizasa; E P Frenkel; J D Minna; T Fujisawa; A F Gazdar
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

Review 10.  Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy.

Authors:  Ido Amit; Ron Wides; Yosef Yarden
Journal:  Mol Syst Biol       Date:  2007-12-04       Impact factor: 11.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.